McKesson Corporation vs PAGSEG Inc — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while PAGSEG Inc trades at $11.16 (market cap $2.94B). The key difference: McKesson Corporation is far larger — about 36.9× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (10.49%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and PAGSEG Inc for 26 Days on average.
| MCK | PAGS | |
|---|---|---|
Market Cap | $108.46B | $2.94B |
Volume | 712,607 | 4,242,708 |
Sector | Health | Industrials |
52-Week High | $995.69 | $12.00 |
52-Week Low | $725.17 | $8.44 |
Typical Hold Time | 74 Days | 26 Days |
Enterprise Value | $115.00B | $11.02B |
Dividend Yield | 0.4% | 10.49% |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
PAGS trades at $10.68, up 1.62% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $10.70. The stock shows strong fundamentals with a P/E of 7.1, net income margin of 10.45%, and a dividend yield supported by a recent $0.28 payout. Recent earnings beat expectations in Q2 2026, and cash flow from operations remains robust at $7.56 billion for 2025.
The outlook is positive given undervaluation metrics and institutional support, but risks include a projected negative net cash flow for 2026 and high RSI levels suggesting overbought conditions. Earnings growth and banking segment expansion are key catalysts, while macroeconomic pressures in Brazil present headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →